Ipca Laboratories Limited

Ipac Laboratories Limited

Ashok Kumar

Dharmendra Singh

Satish Rajanikant Soudagar

Nellithanath Thankachen Byju

Suneel Yeshwant Dike

Nalinakshya Balaram Panda

Ganesh Devidas Mahale

Gaurav Sahal

Manmohan Nimbalkar

Abhay Atmaram Upare

Arpana Prashant Mathur

Uttamrao Arjunrao Sawant

Swapnali Hemant Patil

Pramilkumar Mathur

Sanjay Pandurang Gawade

Chirag Hasmukh Shah

Dinesh Kanji Bhadra

Devki Moje

Sandeep Madhavrao Burudkar

Sanjay Tukaram Gunjal

Dilip Uttam Jadhav

Mathur Arpana

Atul Jadhav

Navinchandra Darpan Pandya

Balasaheb Ganpat Jadhav

Shankar Deepak Panmand

Prashant Gautam

Lavkesh Dayashankar Kushwaha

Byju Nellithanath Thankachen

Ashvini Saxena

Gunjan Pramod Pathak

Virendra Pal

Rakesh Kumar Bhasin

Brajesh Sharma

Rahul Karde

Ramsingh Gajendrasingh Thakur

Ragneshkumar Rana

Thankachen Byju Nellithanath

Avinash Manohar Nijasure

Manavalan Saravanan

Pramil Kumar Mathur

Ragnesh Kumar Rana

Rajesh Kumar Keshava Prasad Singh

Jaysingh Gehlot

Swapnil Shreekant Kore

Vijaya Bhaware

Durga Prasad Samantaray

Mahesh Kharade

Ashvini Kumar Nand Kishore Saxena

Rajeshkumar Singh

Vitthal Syryabhan Buchude

Ketan Dhansukhlal Vyas

Vitthal Suryabhan Buchude

Sanjay Govind Barve

Priti Jayesh Bhayani

Sanjay Nandavadekar

New compounds, namely, (7aS,2'S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.

Anti-thrombotic compounds

The present invention relates to a novel pharmaceutical composition having enhanced bioavailability through improved aqueous dissolution of poorly water soluble drugs, and to a method for preparing it. The invention more particularly relates to an oral pharmaceutical composition containing active ingredients of poor aqueous solubility, more specifically, antiparasitic and antipneumocystic drug Atovaquone alone or in combination with Proguanil.

Pharmaceutical composition

The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.

Methods for the treatment or prophylaxis of thrombosis or embolism

Disclosed are complexes of an antipneumocystic compound and an antimalarial compound, processes for their preparation, pharmaceutical compositions and methods of using said complexes or compositions for the treatment and/or prophylaxis of parasitic infections.

Complex for treatment and/or prophylaxis of parasitic infections

Solid forms of methyl (7aS,2'S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate

Disclosed herein is an industrial preparation of Quetiapine by the reaction of 11-piperazinyldibenzo[b,f][1,4]-thiazepine or its salt with 2-(2-chloroethoxy)ethanol in presence of an organic or inorganic base under neat or aqueous condition to form 11-[4-{2-(2-hydroxyethoxy)ethyl}-1-piperazinyl]dibenzo[b,f]-[1,4]thiazepine. The quetiapine free base obtained is further converted to its hemi-fumarate salt.

Industrial preparation of 11-[4-{2-(2-hydroxyethoxy) ethyl}-1-piperazinyl] dibenzo [b,f]-[1,4]thiazepine

Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as 'Form IPCA-ATO,' and the preparation thereof.

Process for preparation of atovaquone and novel intermediates thereof

The present invention relates to a process for preparation of isotretinoin and more specifically, to a purification process for obtaining highly pure isotretinoin that is useful as a keratolytic agent, particularly useful for the treatment of acne. The process involves treating isotretinoin containing metal contamination and/or other impurities with a base in a suitable solvent to form a solution of isotretinoin, followed by adsorption, precipiation, and filtration or centrifugation.

Process for preparation of highly pure isotretinoin

An improved process for the manufacture of Clopidogrel starting from 2-(2-thienyl) ethylamine, which eliminates the isolation of an unstable intermediate like 2-(2-thienyl) ethyl formimine by subjecting it to a one pot cyclization to get 4, 5, 6, 7-tetrahydrothieno (3,2-c) pyridine of Formula II and further reacting with halo-compound of Formula III (where X is Cl or Br) at 20 to 90&#xb0; C. temperature characterized in a solvent like water and/or dichloroethane in presence of organic or inorganic bases is disclosed herein. This invention further discloses a process for resolution of racemic Clopidogrel into its optical antipodes and converting the dextroclopidogrel base into its known polymorphs namely 'Form I' or 'Form II' in solvents selected from methyl propyl ketone, methyl isopropyl ketone, diethyl ketone or their mixture thereof, mixture of ethyl acetate and methyl propyl ketone, mixture of ethyl acetate and methyl isopropyl ketone, or mixture of ethyl acetate and diethyl ketone or ethyl acetate.

Industrial process for preparation of Clopidogrel hydrogen sulphate

New compounds useful as synthetic intermediates to synthesize perindopril, a new process for synthesizing perindopril, and new salts of perindopril.

Process for manufacture of pure (2S, 3aS, 7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl) butyl]amino]-1-oxopropyl] octahydro-1H-indole-2-carboxylic acid and its tert. butyl amine salt

A one-pot industrial process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one of Formula-(I) from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one of Formula-(IV) involves reaction of Formula (IV) with HNRRsalt and paraformaldehyde, where R,Rare independently alkyl groups or together forms a cyclic alkyl group, in a solvent system of acetic acid and hydrocarbon solvent to form a crude mixture of intermediate compounds of Formula (III) and (VIII), which is converted to ondansetron (Formula (I)) without isolation by reaction with 2methyimidazole in a suitable solvent system in the same pot.

One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O

A process for the resolution of isomeric tramadol mixtures comprising: providing a purification stock comprising both cis and trans tramadol; contacting the purification stock with an acid under conditions effective to form an acid salt of the cis and trans tramadol in the purification stock; and separating the cis tramadol acid salt from the trans tramadol to obtain a purified cis tramadol acid salt; and optionally converting the cis tramadol acid salt to cis tramadol or to a pharmaceutically active salt thereof.

Tramadol recovery process

The present invention discloses selective and complete reduction of pyridine ring in a biaryl system comprising &#x221d;-substituted or non-substituted benzene ring and relates more specifically, not exclusively, for the manufacture of methylphenidate, which is used for treatment of Attention Deficit Hyperactive Disorder (ADHD) and also acts as central nervous system stimulant, by using palladium/C in a solvent such as C1-C4 alcohols in presence of molar quantities of organic and/or inorganic acids.

Manufacturing process for methyl phenidate and intermediates thereof

The preset invention relates to a cost effective, high yielding, reproducible method for the manufacture of alendronic acid or its salt, such as sodium alendronate, from inexpensive and readily available pyrrolidone using phosphonating agents such as PClin the presence of acids such as sulphonic acids, sulphuric acid or phosphoric acid, and pharmaceutical dosage forms of alendronic acid or pharmaceutically acceptable salts thereof.

Process for manufacture of 4-amino-hydroxybutylidene-1, 1-bisphosphonic acid and its salts

Growing community of inventors

Mumbai, India

Ashok Kumar